Metastatic pancreatic cancer |
First-line metastatic therapy |
Napabucasin plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine |
Metastatic pancreatic cancer |
First-line metastatic therapy |
PEGPH20 plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine |
Locally advanced or metastatic pancreatic cancer |
First-line advanced therapy |
NC-6004 with Gemcitabine versus Gemcitabine alone |
gBRCA-mutated metastatic pancreatic cancer whose disease has not progressed on first-line platinum-based chemotherapy |
Patients are on treatment with a first line platinum-based metastatic therapy without progression |
Maintenance Olaparib monotherapy versus Placebo |
K-RAS wild-type locally advanced and metastatic pancreatic cancer |
Must have had no anti-tumor palliative chemotherapy or molecularly targeted therapy. Adjuvant therapy must have been more than 6 months prior. |
Nimotuzumab with Gemcitabine versus Placebo with Gemcitabine |
Locally advanced and/or metastatic pancreas cancer that failed FOLFIRINOX |
Secord-line metastatic therapy |
Endo TAG-1 plus Gemcitabine versus Gemcitabine alone |
Metastatic pancreatic cancer previously treated with gemcitabine |
Second-line metastatic therapy |
Glufosfamide versus Fluorouracil |
Metastatic pancreatic cancer that has progressed during or following a first-line gemcitabine containing regimen |
Second-line metastatic therapy |
AM0010 with FOLFOX versus FOLFOX alone |
Locally advanced or metastatic pancreatic cancer |
Second-line therapy for progressive advanced pancreatic cancer or progression after resection |
GV1001 with Gemcitabine/Capecitabine versus gemcitabine/Capecitabine alone |